Thrombophilia and hormonal therapy in transgender persons: A literature review and case series

被引：4

作者：

Kerrebrouck, Marianne ^{[1
]}

Vantilborgh, Anna ^{[2
]}

Collet, Sarah ^{[1
]}

T'Sjoen, Guy ^{[1
]}

机构：

[1] Ghent Univ Hosp, Dept Endocrinol, Heymanslaan 10, B-9000 Ghent, Belgium

[2] Ghent Univ Hosp, Dept Hematol, Ghent, Belgium

来源：

INTERNATIONAL JOURNAL OF TRANSGENDER HEALTH | 2022年 / 23卷 / 04期

关键词：

Anticoagulation; hormonal therapy; thrombophilia; thrombosis; transgender; case series; guidance; FACTOR-V-LEIDEN; PROTEIN-C DEFICIENCY; DEEP-VEIN THROMBOSIS; TERM-FOLLOW-UP; VENOUS THROMBOEMBOLISM; POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; HEMOSTATIC VARIABLES; TESTOSTERONE TREATMENT; ORAL-CONTRACEPTIVES;

D O I：

10.1080/26895269.2022.2025551

中图分类号：

B849 [应用心理学];

学科分类号：

040203 ;

摘要：

Background: Venous thromboembolism (VTE) is a rare side effect of hormonal therapy in transgender persons. Prothrombotic genetic variants can increase this risk. For this reason, previous VTE and/or genetic thrombophilia may be considered by some as contraindications to hormonal treatment. Aim: To formulate directions for clinical practice about the indications for thrombophilia screening and when to consider combination therapy of therapeutic anticoagulation and hormonal treatment as a safe alternative to withholding hormonal treatment. Methods: We conducted a literature search and describe a case series. All adult patients with gender dysphoria and a known prothrombotic genetic variant or history of VTE were invited by letter to participate in this study. Results: In our center, thrombophilia screening before start of hormonal treatment was restricted to those with a personal or family history of VTE. Sixteen individuals with a history of VTE and/or an underlying prothrombogenic condition were described. The time of follow up varied from 4 months to 20 years. Seven trans women had a positive thrombophilia screening (2 Factor V Leiden (FVL), 1 FVL + anticardiolipin antibodies, 1 FVL + high Factor VIII coagulant activity, 1 protein C deficiency, 1 prothrombin mutation, 1 positive lupus anticoagulant). Three trans women experienced an unprovoked VTE after start of hormonal therapy of which one lead to a positive thrombophilia screening. One VTE event in a trans woman was assumed to be provoked by surgery. Five trans men were identified with a prothrombogenic mutation (3 FVL, 1 protein C deficiency, 1 prothrombin mutation). One trans man, with a negative thrombophilia screen, experienced multiple provoked VTE events before start of hormonal therapy. Conclusion: Based on our literature review and case series we offer guidance when confronted with patients with previous VTE and/or genetic thrombophilia requesting hormonal interventions.

引用

页码：377 / 391

页数：15